Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
P&G: Challenges ahead - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Mar 20, 2001

    P&G: Challenges ahead

    Procter & Gamble Hygiene and Healthcare Ltd. (PGHH) has witnessed a steep decline in its price over the last one-year. The company’s falling brand image and increasing competition is a real concern making the stock an under-performer.

    PGHH’s topline growth in the last two years slowed down to a single digit due to stiff competition in the markets from low priced packs. Also the unorgainsed sector gave a tough time to the company.

    Its strategy of focusing on premium segment of the market has however led to a continuous improvement in its operating margins (25.8%), which are among the highest in the FMCG industry. While the company’s revenues grew at a compounded annual growth rate of 6.2% in the past 5 years, profits showed an encouraging growth rate of 27.5%.

    Comparative margins
    Companies OPM NPM
    PGHH 26% 18%
    HLL 14% 12%
    Colgate 8% 5%
    Nestle 17% 7%
    Cadbury 17% 9%
    SmithKline Consumer 16% 13%

    PGHH’s focus on two brands is a concern considering the drop in the topline growth. During the first half of the year ended June ’01, the company’s sales inched up by just 1%. However, the company managed to put in a good performance by improving its operations. PGHH improved its operating margins by 360 basis points (3.6%) in the time frame of 6 months by controlling expenditure. It also pruned its debt burden. As a result, its interest costs were zero during the quarter. These operating and working capital efficiencies fueled its profits growth by 26% during the first half of the year.

    At the current market price of Rs 590, PGHH is trading at a P/E of 14 times its June 2001 projected earnings, which is at a significant discount compared to its peers in the industry. Its markets cap to sales ratio of 2.5 times is however in line with other companies. The stock is given low valuation by the markets because the company is highly dependent on two brands. Global competitors in healthcare and feminine hygiene category are waiting in the wings to enter the Indian market with superior products based on the latest technology. PGHH is positioning itself to face the challenges by making operational changes and focusing on the long-term strategic benefits, which its present brand offers.

    The risk of a limited product profile is not likely to affect PGHH's topline growth since the company is the market leader in both the brands and is continuously investing in brand promotion and innovation to maintain its position. For PGHH it is very challenging to bring back the real glory in both its main brands i.e. ‘Vicks’ and ‘Whisper’. Growth in both these brands would really bring the de-risking perception among the investors, and help re-rate its business from the present levels.

    Stock performance
    Particulars Price (Rs) 3 months 1 year 2 years
    PGHH 590 -14.7% -1.2% -41.2%



    Equitymaster requests your view! Post a comment on "P&G: Challenges ahead". Click here!


    More Views on News

    P&G: Strong Core Growth (Quarterly Results Update - Detailed)

    Dec 9, 2016

    Procter & Gamble Hygiene and Health Care has announced the first quarter results of the financial year ended June 2017 (1QFY17). The company's sales rose by 12.5%YoY while net profit rose by 50.1% YoY during the quarter.

    P&G: Strong Core Performance (Quarterly Results Update - Detailed)

    Oct 5, 2016

    Procter & Gamble Hygiene and Health Care reported a 0.1% YoY growth in sales and a 2.2% YoY increase in net profits during the quarter ended June 2016.

    GSK Consumer: On the Recovery Path (Quarterly Results Update - Detailed)

    Jun 20, 2017

    While GSK consumer reported muted revenue growth, volumes are seen to be recovering.

    P&G: A Stable Quarter (Quarterly Results Update - Detailed)

    May 6, 2016

    Procter & Gamble Hygiene and Health Care reported an 11% YoY increase in revenues, while profits rose by 12% YoY during the quarter.

    P&G: Margins Go Through the Roof (Quarterly Results Update - Detailed)

    Feb 9, 2016

    Procter & Gamble Hygiene and Health Care reported an 11% YoY increase in revenues, while profits rose by 62% YoY during the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in P&G HYGIENE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Detailed Financial Information With Charts